Abstract:Tumor immunotherapy has emerged as a promising approach in cancer treatment in recent years, offering vast potential. This method primarily involves targeting and inhibiting the suppressive checkpoints present in different immune cells to enhance their activation, ultimately leading to tumor regression. However, tumor cells exploit the surrounding immune cells and tissues to establish a tumor microenvironment (TME) that supports their survival and growth. Within the TME, the efficacy of effector immune cells is compromised, as tumor cells exploit inhibitory immune cells to suppress their function. Furthermore, certain immune cells can be co-opted by tumor cells to facilitate tumor growth. While significantly enhancing the body's tumor immunity can lead to tumor regression, it can also result in severe toxic side effects and an inflammatory factor storm. As a consequence, patients often discontinue treatment due to immune-related adverse events (irAEs) or, in extreme cases, succumb to toxic side effects before experiencing tumor regression. In this analysis, we examined several remission regimens for irAEs, each with its own drawbacks, including toxic side effects or suppression of tumor immunotherapy, which is undesirable. A recent research study, specifically aimed at downregulating intestinal epithelial barrier permeability, has shown promising results in reducing the severity of inflammatory bowel disease (IBD) while preserving immune function. This approach effectively reduces the severity of IBD without compromising the levels of TNF-α and IFN-γ, which are crucial for maintaining the efficacy of tumor immunotherapy. Based on the substantial similarities between IBD and ICI colitis (combo immune checkpoint inhibitors-induced colitis), this review proposes that targeting epithelial cells represents a crucial research direction for mitigating irAEs in the future.

The Less-Recognized Therapeutic Targets in Inflammatory Bowel Disease and Colorectal Cancer

[Characteristics of intestinal tuft cells and their role in the pathomechanism of inflammatory bowel disease and colorectal carcinoma]

Tuft Cells and Their Role in Intestinal Diseases

Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting

Tuft cells in the intestine, immunity and beyond

Targeting of Costimulatory Molecules As a Therapeutic Approach in Inflammatory Bowel Disease

Microbiota-specific Th17 Cells: Yin and Yang in Regulation of Inflammatory Bowel Disease.

Targeting T and B Lymphocytes in Inflammatory Bowel Diseases: Lessons from Clinical Trials

Toll like receptor signaling pathway as a potential therapeutic target in colorectal cancer

An update on the biological characteristics and functions of tuft cells in the gut

Role of MicroRNAs in Regulating T Cell Responses in Inflammatory Bowel Disease

The role of IL-17-producing Foxp3+ CD4+ T cells in inflammatory bowel disease and colon cancer

Therapeutic Potential of Tolerogenic Dendritic Cells in IBD: From Animal Models to Clinical Application

Cytokine-Induced Modulation of Colorectal Cancer

The Cytokine Network in Colorectal Cancer: Implications for New Treatment Strategies

Inflammatory regulatory T cells in the microenvironments of ulcerative colitis and colon carcinoma.

The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in Colorectal Cancer

Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: Emerging avenue for targeted therapy

The Role of the Immune System in IBD-Associated Colorectal Cancer: From Pro to Anti-Tumorigenic Mechanisms

Unveiling the Key Regulators

Molecular Mechanisms of Tumor Immunomodulation in the Microenvironment of Colorectal Cancer